Von Hippel-Lindau Disease Drug Pipeline Analysis Report 2025

Report Coverage

The Von Hippel-Lindau Disease Drug Pipeline Report by Expert Market Research gives comprehensive insights into Von Hippel-Lindau disease drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Von Hippel-Lindau disease. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The Von Hippel-Lindau disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Von Hippel-Lindau disease. 

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing Von Hippel-Lindau disease pipeline development activities.   

Von Hippel-Lindau Disease Drug Pipeline Outlook 

Von Hippel-Lindau disease is an autosomal dominant condition in which tumors and cysts are formed in different parts of the body. These growths can be benign or cancerous. The disease is caused by mutations in the VHL tumor suppressor gene. Hemangioblastomas (in the brain and spinal cord), renal cell carcinoma (in the kidneys), and pheochromocytomas (in the adrenal glands), among others, include the common tumors associated with Von Hippel-Lindau disease.

Surgery is commonly used to remove tumors that become malignant or cause significant issues. Advances in precision medicine and the growing focus on targeted approaches based on specific molecular pathways are anticipated to positively influence the drug pipeline landscape. Moreover, new drugs targeting HIF-2α and other pathways linked to Von Hippel-Lindau disease are likely to improve patient outcomes in the coming years.

Von Hippel-Lindau Disease – Drug Pipeline Therapeutic Assessment

Von Hippel-Lindau Disease Pipeline Assessment Segmentation, By Phases 

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for Von Hippel-Lindau disease. 

Von Hippel-Lindau – Pipeline Assessment Segmentation, By Drug Classes 

The drug molecule categories covered under the Von Hippel-Lindau disease pipeline analysis include hypoxia-inducible factor (HIF) inhibitors, mTOR inhibitors, and VEGF pathway inhibitors. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Von Hippel-Lindau disease.

Von Hippel-Lindau Disease Clinical Trials Therapeutic Assessment – Competitive Dynamics 

The EMR Von Hippel-Lindau drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Von Hippel-Lindau Disease clinical trials: 

• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Betta Pharmaceuticals Co., Ltd.
• Peloton Therapeutics, Inc. (a subsidiary of Merck & Co., Inc.)
• Novartis Pharmaceuticals

Von Hippel-Lindau Disease Emerging Drugs Profile 

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Von Hippel-Lindau disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Von Hippel-Lindau disease drug candidates.

Drug: Belzutifan

Description 1: Sponsored by Peloton Therapeutics, Inc. (a subsidiary of Merck & Co., Inc.), the objective of this open-label Phase 2 clinical trial is to investigate the efficacy and safety of orally administered belzutifan treatment in an estimated 50 participants with Von Hippel-Lindau disease with at least 1 measurable renal cell carcinoma tumor.

Drug: Oral HS-10516

Jiangsu Hansoh Pharmaceutical Co., Ltd. is conducting a Phase I multi-center clinical trial to inves...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report 

The Von Hippel-Lindau Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Von Hippel-Lindau disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Von Hippel-Lindau disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Von Hippel-Lindau Disease Pipeline Insight Report 

• Which companies/institutions are leading the Von Hippel-Lindau disease drug development?
• What is the efficacy and safety profile of Von Hippel-Lindau disease pipeline drugs?
• Which company is leading the Von Hippel-Lindau disease pipeline development activities?
• What is the current Von Hippel-Lindau disease commercial assessment?
• What are the opportunities and challenges present in the Von Hippel-Lindau disease drug pipeline landscape?
• What is the efficacy and safety profile of Von Hippel-Lindau disease pipeline drugs?
• Which company is conducting major trials for Von Hippel-Lindau disease drugs?
• Which companies/institutions are involved in Von Hippel-Lindau disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Von Hippel-Lindau disease?

Related Reports

Von Hippel-Lindau Disease Market

Global Clinical Trials Market